Skip to content

Clinical and Laboratory Analysis of Familial Cancer

Clinical and Laboratory Analysis of Familial Cancer

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02565004
Enrollment
19
Registered
2015-10-01
Start date
2015-09-28
Completion date
2020-07-31
Last updated
2022-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Keywords

Genetic, Sample Collection, Natural History

Brief summary

Background: DNA makes up the instruction book for people s cells. Cancer is a disease caused by DNA changes that build up and affect cell function. Researchers want to learn more about what may cause cancer by testing the DNA of people with the disease and their family members. Objective: To find DNA changes that may be inherited and may cause or influence whether a person gets cancer. To study families with clusters of cancer to find out if there is a DNA mutation specific to certain cancers. Eligibility: People 18 years of age and older who: Participated in the familial genetic part of NIH study 09-C-0079, a previous study or had family members enrolled in this study Design: Participants may have been screened in the previous study. They will give permission for researchers to use their data and their tissue or blood samples collected in the study. Participants may give blood samples. At each stage of testing, participants will meet with a genetics health care provider. The provider will explain the tests and answer questions. If researchers find a DNA change that might increase the risk for cancer or other health issues, they will confirm this result in a testing lab. This will require a blood sample. Participants personal DNA data and health information will be put in a database for research purposes.

Detailed description

Background: * This study is to continue the analysis begun on 09C0079 which was focused on identification of the genetic mutation associated with a new gastric polyposis syndrome, Gastric Adenocarcinoma and Proximal Polyposis of the Stomach (GAPPS). * GAPPS is an autosomal dominant gastric polyposis syndrome that confers a substantial risk for gastric adenocarcinoma and has been found to be associated with germline point variants in APC promoter 1B. * At this time, any non-gastric phenotype associated with GAPPS is unknown and is being explored using a phenotyping survey interview. Objective \- To specifically investigate families with clusters of cancer to determine if there is a potential familial genetic mutation specific to a particular cancer and if present, to compare these genetic abnormalities with individuals from the same family without cancer. Eligibility: * Participants must meet one of the following: * Have been previously enrolled on the familial genetic analysis arm of NIH study 09-C-0079; OR * Be family members of patients previously enrolled on the familial genetic analysis arm of 09-C-0079; OR * Have a documented pathogenic germline APC promotor 1B variant from a CLIA approved laboratory. * Participants must be 10 years of age or older Design: * This protocol was originally opened to continue same use of research that was approved under protocol 09-C-0079, to analyze the data for publication, and to provide participants with any results of clinical and analytic validity and clinical utility. * In a subsequent amendment carriers of a germline APC promoter 1B variant will participate in a phenotyping assessment survey interview to assess the phenotype of Gastric Adenocarcinoma and Proximal Polypopsis of the Stomach (GAPPS).

Interventions

None listed

Sponsors

National Cancer Institute (NCI)
Lead SponsorNIH

Study design

Observational model
FAMILY_BASED
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
10 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* INCLUSION CRITERIA: * Participants must meet one of the following: * Have been previously enrolled on the familial genetic analysis arm of NIH study 09-C-0079; OR * Be family members of patients previously enrolled on the familial genetic analysis arm of 09-C-0079; OR * Have a documented pathogenic germline APC promotor 1B variant from a CLIA approved laboratory. * Participants must be 10 years of age or older

Exclusion criteria

Inability to provide informed consent.

Design outcomes

Primary

MeasureTime frameDescription
investigate relationship of familial genetic mutation to a particular cancer1 yearlinkage analysis performed for familial clustering of malignant and pre-malignant disease in families

Secondary

MeasureTime frameDescription
To assess the phenotype of Gastric Adenocarcinoma and Proximal Polyposis of the Stomach (GAPPS)1-2 yearsDescriptive statistics such as median, mean and standard deviation will be calculated for all continuous quantitative variables, including age of diagnosis, frequency and duration of symptoms and medication dosage. Frequency data will be calculated for categorical variables.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026